Insilico Medicine leverages AI to identify promising new target for breast and gyneco

[News]

Insilico Medicine("Insilico"), a clinical stage generative artificial intelligence (AI)-driven drug discovery company, recently published an early research that it has identified MYT1 as a promising new therapeutic target for breast and gynecological cancer, and discovered a series of novel, potent, and highly selective inhibitors specifically targeting MYT1.

More... (https://www.news-medical.net/news/20240119/Insilico-Medicine-leverages-AI-to-identify-promising-new-target-for-breast-and-gynecological-cancers.aspx)